Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 07, 2024 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Phase 1 data for CRB-701 (SYS6002) to be presented at ASCO Annual Meeting on June 1, 2024 $116M of capital raised in Q1 2024 extending cash runway through Q1 2027 Appointed Dr. Dominic...
Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum
May 01, 2024 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of...
Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO Annual Meeting
April 24, 2024 16:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that an abstract providing updated data from the...
Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC
April 02, 2024 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Study enrolling patients with metastatic urothelial cancer (mUC) and other Nectin-4 enriched tumorsEmerging clinical profile from CSPC’s Phase 1 China study indicates differentiation from PADCEV ...
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
March 12, 2024 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Encouraging CRB-701 (SYS6002) First-in-Human Data Presented at ASCO-GU 2024; first patient expected to be dosed in US Ph1 study by end of March 2024 IND Application for CRB-601 cleared; Ph1...
Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit
March 06, 2024 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer...
Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer
February 28, 2024 08:00 ET
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today...
Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 06, 2024 09:50 ET
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer...
Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
February 02, 2024 16:01 ET
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today...
Corbus Pharmaceuticals Announces Pricing of Public Offering
January 31, 2024 09:19 ET
|
Corbus Pharmaceuticals Holdings, Inc.
NORWOOD, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today...